IP Library Granted Patent US 10,729,667
Granted Patent B2
US 10,729,667 · App. 16/195,153 · Granted Aug 4, 2020

Topical compositions and methods for making and using same

Inventors: Bhushan Hardas (Summerville, NC); Donna Dalton (High Point, NC); Petra Scheppler (Mainz, DE); Anja Buch (Eschborn, DE); Peter Boderke (Schwalbach, DE)
A61K31/137A61K9/0014A61K9/06A61K31/00A61K31/568A61K31/569A61K47/10A61K47/18A61K47/183A61K47/26A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,729,667
App. No.
16/195,153
Granted
Aug 4, 2020
Kind
B2
Abstract

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Claims (24)

1. A gel composition for topical administration comprising:

(i) naftifine or a pharmaceutically acceptable salt thereof, present in an amount of from about 0.5 wt % to about 4 wt %;

(ii) a solvent comprising a glycol solvent component and an alkyl alcohol solvent component, present in an amount of from about 10 wt % to about 50 wt %;

(iii) a hydroxy cellulose, present in an amount of from about 0.75 wt % to about 2.25 wt %;

(iv) a polysorbate solubilizing agent present in an amount of from about 3 wt % to about 8 wt %;

(v) an amine pH adjuster in an amount of from about 0.12 wt % to about 0.23 wt %; and

one or more of: water, a preservative, a chelating agent, a coloring agent, and a fragrance.

2. The gel composition of claim 1 , wherein the naftifine or a pharmaceutically acceptable salt thereof is present in an amount of from about 1.0 wt % to about 3.0 wt %.

3. The gel composition of claim 1 , wherein the glycol solvent is present in an amount of about 18 wt % to about 22 wt %.

4. The gel composition of claim 3 , wherein the glycol solvent is propylene glycol.

5. The gel composition of claim 1 , wherein the alkyl alcohol is present in an amount of from about 17 wt % to about 22 wt %.

6. The gel composition of claim 5 , wherein the alkyl alcohol is ethanol.

7. The gel composition of claim 1 , wherein the hydroxy cellulose is hydroxyethyl cellulose.

8. The gel composition of claim 1 , wherein the polysorbate solubilizing agent is Polysorbate 20.

9. The gel composition of claim 1 , wherein the polysorbate solubilizing agent is Polysorbate 80.

10. The gel composition of claim 1 , wherein the naftifine, or pharmaceutically acceptable salt thereof, is naftifine hydrochloride.

11. The gel composition of claim 1 , wherein:

the naftifine, or a pharmaceutically acceptable salt thereof, is present in an amount of about 2.0 wt %,

the glycol solvent is present in an amount of about 20 wt %,

the alkyl alcohol solvent is present in an amount of about 19 wt %,

the hydroxy cellulose is present in an amount of about 1.75 wt %, and

the polysorbate solubilizing agent is present in an amount of about 5 wt %.

12. The gel composition of claim 11 , wherein the glycol solvent is propylene glycol.

13. The gel composition of claim 11 , wherein the alcohol solvent is ethanol.

Assignments (3)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: SEBELA IRELAND LIMITED
To: LEGACY PHARMA INC.
Reel/Frame 070028/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: SEBELA INTERNATIONAL BERMUDA LIMITED
To: SEBELA IRELAND LIMITED
Reel/Frame 049791/0116 →
Continuity (5)
Continuation 15255464 · Sep 2, 2016
Continuation 14764545
Continuation In Part 13941201 · Jul 12, 2013
Continuation In Part 13756392 · Jan 31, 2013
Related Publication 20190099388A1 · Apr 4, 2019